期刊
CURRENT HYPERTENSION REPORTS
卷 15, 期 1, 页码 59-70出版社
SPRINGER
DOI: 10.1007/s11906-012-0323-2
关键词
Renin angiotensin aldosterone system; Angiotensin II; Insulin resistance; Aldosterone; Insulin signaling; Angiotensin converting enzyme; Angiotensin 1-7; Diabetes mellitus; Glucose metabolism; Skeletal muscle; Adipocytes; Pancreas; Insulin secretion; Inflammation; Genetics; Polymorphisms; Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Insulin sensitivity; Human studies; Animal models; Renin inhibitor; Obesity; Hypertension; Clinical trials
资金
- NIH/NHLBI [K24HL103845]
- NIH/NINR [F32NR013318]
Alterations in the renin angiotensin aldosterone system (RAAS) contribute to the underlying pathophysiology of insulin resistance in humans; however, individual differences in the treatment response of insulin resistance to RAAS blockade persist. Thus, understanding inter-individual differences in the relationship between the RAAS and insulin resistance may provide insights into improved personalized treatments and improved outcomes. The effects of the systemic RAAS on blood pressure regulation and glucose metabolism have been studied extensively; however, recent discoveries on the influence of local tissue RAAS in the skeletal muscle, heart, vasculature, adipocytes, and pancreas have led to an improved understanding of how activated tissue RAAS influences the development of insulin resistance and diabetes in humans. Angiotensin II (ANGII) is the predominant RAAS component contributing to insulin resistance; however, other players such as aldosterone, renin, and ACE2 are also involved. This review examines the role of local ANGII activity on insulin resistance development in skeletal muscle, adipocytes, and pancreas, followed by a discussion of the other RAAS components implicated in insulin resistance, including ACE2, Ang1-7, renin, and aldosterone.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据